This article is more than 5 years old. Information may no longer be current.

Trial Scorecard: VEST

Issue: April 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Researchers analyzed a wearable cardioverter defibrillator (LifeVest, Zoll Medical) and its impact on mortality in patients with high risk for arrhythmias after MI.

Editor’s Note: This Scorecard was updated on April 10, 2018 to correct the number of centers in the VEST trial. The Editors regret the error.